• February 8, 2023

The Rise Of Spatial Thinking: The New Frontier For Insight-Driven Business

In our data-rich world, here’s the most fascinating aspect of spatial analysis: The more complex the problem, the more multi-layered it is, the more powerful spatial analysis is. Understanding and managing …

Pentagon Warns China Has More Nuclear Missile Launchers Than U.S. But There’s One Big Catch

The Pentagon has warned lawmakers on Capitol Hill that China now has more ground-based facilities capable of launching nuclear missiles than the U.S., according to a new report from the Wall …

Could Sustainable Investing For Retirement Increase Or Decrease Your Investment Returns?

If you’d like to align your retirement investments with your values regarding environmental and social goals, then an important question to ask yourself is whether focusing on sustainable investments will create …

The stock market bounced back from its worst first half in 52 years with its best month since November 2020, as the S&P 500 index gained 9.1% in July, trimming its year-to-date losses to 13.3%.

Stocks shrugged off news this week of the GDP contracting for a second straight quarter, a common indicator of a looming recession, and another 75 basis point interest rate hike by the Federal Reserve on Wednesday. The S&P 500 gained 5.3% in just the last three trading days of the month. Some experts think recessionary fears were already priced in, and second-quarter earnings over the last couple weeks have generally been better than the low expectations investors were bracing for.


The top-performing stock in the S&P 500 was Enphase Energy (ENPH), a solar technology company which jumped 46%, mostly in the last three days after it reported second-quarter earnings. Its revenue for the quarter grew 68% year over year to $530 million, and net profit nearly doubled to $77 million. The biggest loser in the S&P 500 was Colorado-based gold miner Newmont Corp. (NEM), which fell 24% and underperformed its earnings expectations on Monday.

Growth stocks, among the hardest hit this year, are among the month’s winners. Cryptocurrency exchange Coinbase (COIN) and electric carmaker Rivian (RIVN) both gained more than 30% in July. They’re now down 75% and 67%, respectively, for 2022.

July’s biggest winner was Israeli fintech Pagaya Technologies (PGY), which gained 494% after becoming the newest flavor-of-the-month meme stock for a short squeeze fueled by social media. Pagaya, which uses artificial intelligence for credit approvals, went public in a SPAC merger in June and lost more than 70% in its first few weeks until it shot up 819% since July 19 after a registration statement filed with the SEC revealed it had a float of only 945,000 shares out of 654 million shares outstanding. Pagaya recorded $475 million in revenue on a net loss of $209 million in 2021 and now has a market cap of $12 billion.

In the mid cap range, including stocks between $2 billion and $10 billion in market cap, Chinese software provider WeTrade Group (WETG) led the way, tripling in July. Its main catalyst was a July 18 announcement that it was uplisting to the Nasdaq and offering 10 million shares of stock at $4 per share. Its shares finished the month at $17.32.

Middle-market businesses with crypto exposure also thrived as bitcoin gained close to 20% in July after falling 60% and losing $530 billion in market value in the first half of 2022. Microstrategy (MSTR), a software company which owns about $3 billion worth of bitcoin, and crypto bank Silvergate Capital (SI) both rose 74%.

No midcap business fell more than 30% in July, but the worst performer was MSP Recovery (MSPR), which is down 84% since it went public via a SPAC merger in May. The company, which aims to profit from litigation around Medicare and Medicaid insurance claims, generated just $14.6 million in revenue in 2021, making investors roll their eyes at its implied $32.6 billion valuation at its IPO.

These are the 10 U.S. listed midcap companies that performed the best and worst in July, according to Factset data.

Among small-cap stocks with market values between $300 million and $2 billion, few have fallen farther than Bausch Health (BHC), which crashed 41% in one day on Thursday after a U.S. District Court judge indicated that he will invalidate some of its patents related to its Xifaxan drug to treat irritable bowel syndrome. Competitor Norwich Pharmaceuticals is proposing a generic version of the drug, which generated $1.6 billion in sales for Bausch Health in 2021, 19% of its revenue.

Bausch Health is a Canadian drug developer that was worth as much as $90 billion at its peak in August 2015, when it was known as Valeant Pharmaceuticals, but fell victim to $30 billion in debt after a slew of acquisitions and public backlash to its practices of buying drugs and hiking their prices exponentially. It plunged more than 90% in a span of less than a year, costing hedge funds like Bill Ackman’s Pershing Square billions. It changed its name in 2018 to distance itself from that history, but its stock has kept sliding. It’s down another 83% this year to $4.62 per share, its lowest since 1995.

Most small caps fared much better in July, with the Russell 2000 index up 10.4%, and ten companies doubled in value. Bitcoin miner Marathon Digital (MARA) rose 143% after striking a deal to increase its power supply, and Rhythm Pharmaceuticals (RYTM) tripled thanks to promising data for a drug to treat obesity.

These are the 10 biggest U.S. listed small-cap winners and losers of the month, according to Factset data.


Leave a Reply

Your email address will not be published.